An interventional study of Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator in Premature Ventricular Contractions, sponsored by Konstantinos Siontis. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Konstantinos Siontis · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Ventricular Premature Complexes with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Ventricular Premature Complexes · United States.
Among the 33 studies in Ventricular Premature Complexes with a site in United States, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2027, is one of 12 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 33rd registered.
103 studies on the registry are indexed under Ventricular Premature Complexes; 33 are open to participants now.
Browse Ventricular Premature Complexes studies →11 of the 33 studies in Ventricular Premature Complexes with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 21+
University Hospital, Basel, Switzerland · Sites in United States, Austria, Canada and 13 more countries
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Kansas City Heart Rhythm Research Foundation · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Ventricular Premature Complexes studies recruiting now, 17 (77%) set no upper age limit and 3 (14%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1 · Phase 4 4
First in 2009; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 59 interventional studies indexed under Ventricular Premature Complexes.
Median enrollment 60 across the 20 interventional studies, 200 across the 13 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 33 have an industry lead sponsor. The 10 most frequent:
Konstantinos Siontis is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Konstantinos Siontis has 1 study filed under Ventricular Premature Complexes — fewer than ten, so there is no comparison to draw.
4 of the studies in Ventricular Premature Complexes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04893278Mayo ClinicVirtual Reality in Electrophysiology Laboratory (EP) | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT06747013Vivek ReddyTreatment of Focal Ventricular Tachycardias Using a Pulsed Field Ablation From a Point Ablation Catheter Short Title FOCUS-PFA | 2027-02 |
| NCT07220525University of California, San FranciscoDisrupted Sleep and Concurrent Ectopy or Atrial Fibrillation | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Ventricular Premature Complexes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to understand whether a dual-energy catheter ablation system that uses radiofrequency (RF) and pulsed-field (PF) energy can safely and effectively treat premature ventricular contractions (PVCs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Guideline-supported indication for first-time or redo catheter ablation of PVCs at the judgment of the electrophysiologist. Specifically:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are assigned to receive radiofrequency (RF) followed by pulsed-field (PF) at each selected treatment site. For each PF treatment, 24 PF bursts are delivered. Up to three stacked lesions may be performed at the same location.
Device: Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator
Participants are assigned to receive pulsed-field (PF) alone at each selected treatment site. For each PF treatment, 24 PF bursts are delivered. Up to three stacked lesions may be performed at the same location.
Device: Dual Energy THERMOCOOL SMARTTOUCH™ SF (STSF) Bi-Directional Navigation catheter with TRUPULSE™ Generator
The THERMOCOOL SMARTTOUCH™ SF Bi-Directional Navigation Catheter is an irrigated, contact-force-sensing catheter used to map the heart and deliver radiofrequency (RF) or pulsed-field (PF) energy to selected treatment sites. The catheter is connected to the TRUPULSE™ Generator, which provides both energy types, and to the nGEN™ Pump, which controls saline irrigation. The system is used with the CARTO™ 3 electroanatomic mapping system and workstation with the VISITAG SURPOINT™ Module to display heart anatomy, catheter location, catheter-to-tissue contact, and treatment information during the procedure.
Number of Participants With Successful Delivery of Ablation Lesions Using the Dual-Energy THERMOCOOL SMARTTOUCH SF Catheter With the TRUPULSE Generator
Feasibility is defined as successful delivery of ablation energy at the targeted premature ventricular complex (PVC) site. Delivery counts as successful only if there is no study device deficiency or malfunction that prevents energy delivery, and no need to convert to a bailout ablation approach.
Time frame: During the index ablation procedure
Acute procedural success
Number of participants with elimination of the target premature ventricular contraction by the end of the procedure.
Time frame: End of the ablation procedure
Participants with greater than 80% reduction in target PVC burden
Number of participants with greater than 80% reduction from baseline in the burden of the target premature ventricular contraction on Holter monitoring.
Time frame: 1 month, 6 months
Change in Short Form Health Survey (SF-36) score
The 36-Item Short Form Health Survey (SF-36) is a participant-reported questionnaire that assesses health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Total scores range from 0 to 100. Higher scores indicate better health status.
Time frame: Baseline, 1 month, 6 months
Change in EQ-5D score
The EQ-5D is a participant-reported measure of health-related quality of life covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses across the five dimensions define the participant's health state. Higher scores indicate better health.
Time frame: Baseline, 1 month, 6 months
Number of Participants With New Coronary Artery Stenosis on Coronary CT Angiography at 6 Months After Ablation
Total number of patients with new-onset coronary luminal stenosis found on CT coronary angiography
Time frame: 6 months
Total Procedure Time
Total procedure time will be reported in minutes
Time frame: From start to finish of index ablation procedure
Electrogram endpoints
EGM amplitude changes after PF, RF, and RF-PF lesion delivery
Time frame: Intraprocedure
Ablation Lesion Depth
Maximum depth of the ablation lesion at the target premature ventricular complex (PVC) site. Depth is measured from the endocardial surface on late gadolinium enhancement (LGE) cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in millimeters.
Time frame: 1 month and 6 months after ablation
Ablation Lesion Width
Maximum width of the ablation lesion at the target PVC site, measured on LGE cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in millimeters.
Time frame: 1 month and 6 months after ablation
Ablation Lesion Volume
Total volume of the ablation lesion at the target PVC site, measured on LGE cardiac MRI. Only participants with an evaluable post-ablation MRI are analyzed. Reported in cubic centimeters.
Time frame: 1 month and 6 months after ablation
Number of Radiofrequency (RF) Lesions Delivered per Participant
Total number of RF lesions delivered with the study catheter during the index procedure
Time frame: During the index ablation procedure
Number of Pulsed-Field (PF) Lesions Delivered per Participant
Total number of PF lesions delivered with the study catheter during the index procedure
Time frame: During the index ablation procedure
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 32 interventional studies with no phase under Ventricular Premature Complexes, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 52. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ventricular Premature Complexes →
Konstantinos Siontis